"What is high blood pressure (hypertension)?
High blood pressure, also known as hypertension, affects nearly a third of all Americans. With hypertension, too much force is exerted on the arteries as blood is pumped through. This results "...
Univasc Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Univasc (moexipril hydrochloride) is used to treat high blood pressure (hypertension). It is an ACE (angiotensin converting enzyme) inhibitor. This medication is available in generic form. Common side effects include dizziness, light-headedness, flushing, muscle aches, dry cough or blurred vision as the body adjusts to the medication.
The recommended initial dose of Univasc in patients not receiving diuretics is 7.5 mg, one hour prior to meals, once daily. Dosage should be adjusted according to blood pressure response. The recommended dose range is 7.5 to 30 mg daily. Univasc may interact with gold injections to treat arthritis, lithium, potassium supplements, salt substitutes that contain potassium, or diuretics (water pills). Tell your doctor all medications and supplements you use. Univasc is not recommended for use during pregnancy due to the risk for harm to a fetus. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Univasc (moexipril hydrochloride) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Univasc in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; severe stomach pain; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
- feeling light-headed, fainting;
- urinating more or less than usual, or not at all;
- fever, chills, body aches, flu symptoms;
- tired feeling, muscle weakness, and pounding or uneven heartbeats;
- chest pain;
- swelling, rapid weight gain; or
- jaundice (yellowing of the skin or eyes).
Less serious side effects may include:
- dizziness, drowsiness, headache;
- sleep problems (insomnia);
- dry mouth, sore throat;
- vomiting, diarrhea, constipation; or
- mild skin itching or rash.
Read the entire detailed patient monograph for Univasc (Moexipril) »
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Univasc Overview - Patient Information: Side Effects
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor immediately if any of these unlikely but serious side effects occur: fainting, decreased sexual ability, symptoms of a high potassium blood level (such as muscle weakness, slow/irregular heartbeat).
Tell your doctor immediately if any of these highly unlikely but very serious side effects occur: change in the amount of urine, signs of infection (e.g., fever, chills, persistent sore throat).
This drug may rarely cause serious (possibly fatal) liver problems. If you notice any of the following highly unlikely but very serious side effects, seek immediate medical attention: yellowing eyes or skin, dark urine, stomach/abdominal pain, persistent fatigue, persistent nausea.
A serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Univasc (Moexipril)»
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Univasc FDA Prescribing Information: Side Effects
univasc® has been evaluated for safety in more than 2 500 patients with hypertension; more than 2 50 of these patients were treated for approximately one year. The overall incidence of reported adverse events was only slightly greater in patients treated with univasc® than patients treated with placebo.
Reported adverse experiences were usually mild and transient, and there were no differences in adverse reaction rates related to gender, race, age, duration of therapy, or total daily dosage within the range of 3.75 mg to 60 mg. Discontinuation of therapy because of adverse experiences was required in 3.4% of patients treated with univasc® and in 1.8% of patients treated with placebo. The most common reasons for discontinuation in patients treated with univasc® were cough (0.7%) and dizziness (0.4%).
All adverse experiences considered at least possibly related to treatment that occurred at any dose in placebo-controlled trials of once-daily dosing in more than 1% of patients treated with univasc® alone and that were at least as frequent in the univasc® group as in the placebo group are shown in the following table:
ADVERSE EVENTS IN PLACEBO-CONTROLLED STUDIES
|Cough Increased||41 (6.1)||5 (2.2)|
|Dizziness||29 (4.3)||5 (2.2)|
|Diarrhea||21 (3.1)||5 (2.2)|
|Flu Syndrome||21 (3.1)||0 (0)|
|Fatigue||16 (2.4)||4 (1.8)|
|Pharyngitis||12 (1.8)||2 (0.9)|
|Flushing||11 (1.6)||0 (0)|
|Rash||11 (1.6)||2 (0.9)|
|Myalgia||9 (1.3)||0 (0)|
Other adverse events occurring in more than 1% of patients on moexipril that were at least as frequent on placebo include: headache, upper respiratory infection, pain, rhinitis, dyspepsia, nausea, peripheral edema, sinusitis, chest pain, and urinary frequency. See WARNINGS and PRECAUTIONS for discussion of anaphylactoid reactions, angioedema, hypotension, neutropenia/agranulocytosis, second and third trimester fetal/neonatal morbidity and mortality, hyperkalemia, and cough.
Other potentially important adverse experiences reported in controlled or uncontrolled clinical trials in less than 1% of moexipril patients or that have been attributed to other ACE inhibitors include the following:
Cardiovascular: Symptomatic hypotension, postural hypotension, or syncope were seen in 9/1750 (0.51%) patients; these reactions led to discontinuation of therapy in controlled trials in 3/12 54 (0.2 4%) patients who had received univasc® monotherapy and in 1/344 (0.3%) patients who had received univasc® with hydrochlorothiazide (see WARNINGS and PRECAUTIONS). Other adverse events included angina/myocardial infarction, palpitations, rhythm disturbances, and cerebrovascular accident.
Renal: Of hypertensive patients with no apparent preexisting renal disease, 1% of patients receiving univasc® alone and 2 % of patients receiving univasc® with hydrochlorothiazide experienced increases in serum creatinine to at least 140% of their baseline values (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).
Respiratory: Bronchospasm, dyspnea, eosinophilic pneumonitis.
Urogenital: Renal insufficiency, oliguria.
Neurological and Psychiatric: Drowsiness, sleep disturbances, nervousness, mood changes, anxiety.
Clinical Laboratory Test Findings
Creatinine and Blood Urea Nitrogen
As with other ACE inhibitors, minor increases in blood urea nitrogen or serum creatinine, reversible upon discontinuation of therapy, were observed in approximately 1% of patients with essential hypertension who were treated with univasc®. Increases are more likely to occur in patients receiving concomitant diuretics and in patients with compromised renal function (see PRECAUTIONS, General).
Other (causal relationship unknown)
Clinically important changes in standard laboratory tests were rarely associated with univasc® administration.
Elevations of liver enzymes and uric acid have been reported. In trials, less than 1% of moexipril-treated patients discontinued univasc® treatment because of laboratory abnormalities. The incidence of abnormal laboratory values with moexipril was similar to that in the placebo-treated group.
Read the entire FDA prescribing information for Univasc (Moexipril) »
Additional Univasc Information
Univasc - User Reviews
Univasc User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.